Abstract
Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.
Original language | English (US) |
---|---|
Pages (from-to) | 193-212 |
Number of pages | 20 |
Journal | Primary Care Diabetes |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2020 |
Keywords
- Antihyperglycemic
- Cardiovascular outcome trials
- Cardiovascular risk
- Type 2 diabetes
ASJC Scopus subject areas
- Nutrition and Dietetics
- Internal Medicine
- Endocrinology, Diabetes and Metabolism